$18.30
1.03%
Nasdaq, Nov 17, 04:00 pm EST. Closed.

Innoviva Stock price

$18.49
-2.29 11.02% 1M
-3.31 15.18% 6M
-1.50 7.50% YTD
-3.48 15.84% 1Y
+4.84 35.46% 3Y
+1.16 6.69% 5Y
+7.29 65.09% 10Y
-6.04 24.62% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-0.54 2.84%

AI Insights on Innoviva Insights AI Insights on Innoviva

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$983.1m
Net debt
positive
Cash
$590.1m
Shares outstanding
71.5m
Valuation
P/E
6.9
P/S | estimate
3.0 | 3.0
EV/Sales | estimate
2.2 | 2.2
EV/FCF | ex SBC
5.4 | 5.8
P/B
1.2
Financial Health
Equity Ratio
71.7%
Return on Equity
23.1%
ROCE
11.4%
ROIC
15.8%
Debt/Equity
0.2
Share-Based Compensation & Dilution
SBC | % of Revenue
$13.5m | 3.1%
SBC as % of FCF
7.4%
SBC Growth 1Y
56.4%
Share Count Growth 1Y
-4.3%
Shareholder Yield
4.3%
Financials
Revenue | estimate
$438.3m | $443.2m
EBITDA
$210.7m
EBIT
$170.2m
Net Income
$193.4m
Free Cash Flow | ex SBC
$182.5m | $169.0m
Growth
Revenue | estimate
12.8% | 7.8%
EBITDA
1.3%
EBIT
1.3%
Net Income
51.9%
Free Cash Flow
-2.5%
Margin
Gross
74.5%
EBITDA
48.1%
EBIT
38.8%
Net
44.1%
Free Cash Flow | ex SBC
41.6% | 38.6%
More
EPS
$2.7
FCF per Share
$2.6
Short interest
14.3%
Employees
159
Rev per Employee
$2.6m

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Innoviva forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Innoviva forecast:

Buy
82%
Hold
9%
Sell
9%

Innoviva Events

Past Events
JUN
8
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
FEB
26
Oppenheimer 36th Annual Healthcare Life Sciences Conference
9 months ago

Financial data from Innoviva

Sep '26
+/-
%
438 438
13% 13%
100%
- Direct Costs 112 112
56% 56%
26%
327 327
3% 3%
74%
- Selling and Administrative Expenses 136 136
21% 21%
31%
- Research and Development Expense 20 20
32% 32%
5%
211 211
1% 1%
48%
- Depreciation and Amortization 41 41
1% 1%
9%
EBIT (Operating Income) EBIT 170 170
1% 1%
39%
Net Profit 193 193
52% 52%
44%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
●
13 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ende...
Positive
Invezz
●
about one month ago
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
Neutral
Business Wire
●
3 months ago
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmace...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Mr. Raifeld
Employees 159
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today